Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $26.3 million versus the consensus estimate of $28.2 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.